A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
SHORT SUMMARY (40 words): We describe the safety and efficacy of treating visceral leishmaniasis in patients with HIV-VL coinfection with concurrent intravenous liposomal amphotericin B (AmBisome) and oral miltefosine (Impavido) in India. The regimen was safe, well tolerated, with lower relapse rates than monotherapy. ABSTRACT Background There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas ofdoi:10.1016/j.ijid.2016.02.166 fatcat:lmeimlz42vcehih4p36n7swt2q